Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1(+) triple negative breast cancer cells

Immune check point inhibitors targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1) have shown clinical success in treatment of human malignancies. Triple negative breast cancer (TNBC), which is primarily characterized by high heterogeneity and presence of tumor infiltrating lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohan, Nishant, Hosain, Salman, Zhao, Jun, Shen, Yi, Luo, Xiao, Jiang, Jiangsong, Endo, Yukinori, Wu, Wen Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685513/
https://www.ncbi.nlm.nih.gov/pubmed/31428520
http://dx.doi.org/10.1080/2162402X.2019.1624128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685513/
https://www.ncbi.nlm.nih.gov/pubmed/31428520
http://dx.doi.org/10.1080/2162402X.2019.1624128

Ejemplares similares